EQUITY RESEARCH - COMPANY REPORT

MASTER STYLE

MASTER TB

THAILAND / SERVICES

ลงทุนซื้อกิจการต่อเนื่อง

- MASTER ประกาศจ่ายหุ้นบันผลเป็นครั้งที่สองพร้อมประกาศความตั้งใจที่จะขอย้ายไปจด ทะเบียนใน SET
- ปรับเพิ่มประมาณการอัตราการเติบโตของกำไรปี 2024 ขึ้น 16% เป็น +49% y-y
- คงคำแนะนำซื้อจากแนวโน้มการเติบโตของกำไรสุทธิที่อยู่ในเกณฑ์ดีและสถานะการเงินที่ ดี

ผลประกอบการปี 2023 อยู่ในระดับที่น่าประทับใจ

MASTER รายงานกำไรสุทธิ 4Q23 ทำสถิติสูงสุดใหม่ที่ 164 ลบ. (+64% q-q, +108% y-y) เรา ประทับใจกับชั่วโมงทำงานที่ทำสถิติสูงสุดใหม่ที่ 14,316 ชั่วโมง (+13.7% q-q) คิดเป็นอัตรา การใช้เตียงที่ 73.8% (เทียบกับ 64.9% ใน 3Q23) อัตรากำไรขั้นต้นกระโดดเพิ่มเป็น 63.6% จาก 58.2% ใน 3Q23 โดยได้ปัจจัยหนุนจาก Operating leverage ที่สูงขึ้นหลังบริษัทฯ เริ่มรับรู้ ส่วนแบ่งกำไรจาก 4 บริษัทรวม 5 ลบ. ณ สิ้นปี 2023 MASTER รายงานกำไรสุทธิทำสถิติ สูงสุดใหม่ที่ 416 ลบ. (+38% y-y)

เตรียมย้ายไป SET พร้อมประกาศลงทุนเพิ่ม

บริษัทฯ ประกาศจ่ายหุ้นปันผลในอัตรา 1:0.142857 ซึ่งจะทำให้จำนวนหุ้นเพิ่ม 301.71ล้านหุ้น หลังวันขึ้นประกาศ XD ในวันที่ 4 มี.ค. 2024 หลังจากนั้นบริษัทฯ จะเตรียมยื่นคำขอย้ายไปจด ทะเบียนใน SET นอกจากนี้ MASTER ยังประกาศลงทุนเพิ่มอีก 4 รายการโดยมีมูลค่ารวม 152 ลบ. ประกอบด้วย 1) หุ้น 20% ใน Aesthelis Code ซึ่งเป็นผู้ผลิตซิลิโคนสำหรับใช้ในทาง การแพทย์; 2) หุ้น 35% ใน Me Center Clinic ซึ่งประกอบกิจการคลินิคสุขภาพจิต; 3) หุ้น 40% ใน Aurora Clinic ซึ่งดำเนินกิจการคลินิคเสริมความงาม 2 แห่งและ 4) หุ้น 15% ใน Korawin Holding ซึ่งดำเนินกิจการ Korawin Clinic และ Ronnapee Clinic เราคาดว่า MASTER จะรับรู้ส่วนแบ่งกำไรจาก 4 กิจการดังกล่าวตั้งแต่ 3Q24 เป็นต้นไป

ปรับเพิ่มประมาณการกำไรปี 2024 พร้อมการเติบโตที่ห่าทึ่ง

เราคงมุมมองเชิงบวกเกี่ยวกับแนวโน้มการเดิบโตของ MASTER ในปี 2024 จากการเติบโต ภายในกล่าวคือการรับรู้เตียงผ่าตัดใหม่เต็มปีและเป้าหมายในการเพิ่มสัดส่วนลูกค้าต่างชาติเป็น ประมาณ 30% ของรายได้รวมจาก 26% ใน 4Q23 นอกจากนี้กำไรยังน่าจะได้ปัจจัยหนุนจาก ภายนอกอาทิเช่น การรับรู้ส่วนแบ่งกำไรจากบริษัท 14 แห่ง เราปรับเพิ่มประมาณการส่วนแบ่ง กำไรปี 2024-25 ขึ้น 19-22% เป็น 125 ลบ. และ 137 ลบ. คิดเป็นประมาณ 20% ของประมาณ การกำไรสุทธิปี 2024-25 เพราะฉะนั้นเราจึงปรับเพิ่มประมาณการกำไรสุทธิปี 2024-25 ของเรา ขึ้น 16% และ 13% คิดเป็นอัตราการเติบโตอยู่ที่ 49% y-y และ 10% y-y ตามลำดับ

ราคาเป้าหมายใหม่อย่ที่ 82 บาทก่อน XD และ 72 บาทหลัง XD

หลังปรับประมาณการกำไร เราปรับเพิ่มราคาเป้าหมายของเราเป็น 82 บาทก่อน XD และ 72 บาทหลัง XD (35x ของค่า 2024E P/E) ราคาเป้าหมายก่อน XD น่าจะมี Upside อยู่ 12.7% ในระยะสั้นเราคาดว่ากำไร 1Q24 จะลดลงจาก Low season ในขณะที่ความเสี่ยงขาลงอยู่ที่ส่วน แบ่งกำไรกำไรที่อาจต่ำกว่าคาด



BUY

UNCHANGE

TARGET PRICE	THB82.00
CLOSE	THB72.75
UP/DOWNSIDE	+12.7%
PRIOR TP	THB71.00
CHANGE IN TP	+15.5%
TP vs CONSENSUS	+3.2%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	1,917	2,326	2,556	2,861
Net profit	416	621	685	763
EPS (THB)	1.58	2.35	2.60	2.89
vs Consensus (%)	-	63.0	30.0	21.3
EBITDA	586	719	800	902
Recurring net profit	416	621	685	763
Core EPS (THB)	1.58	2.35	2.60	2.89
Chg. In EPS est. (%)	nm	16.0	12.9	nm
EPS growth (%)	(2.2)	49.2	10.3	11.3
Core P/E (x)	46.1	30.9	28.0	25.2
Dividend yield (%)	0.4	1.0	-	-
EV/EBITDA (x)	32.2	26.7	23.7	20.7
Price/book (x)	6.4	5.6	5.0	4.5
Net debt/Equity (%)	(11.1)	(0.1)	(5.7)	(12.6)
ROE (%)	24.5	19.4	18.9	18.8



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	13.7	36.6	5.6
Relative to country (%)	11.4	38.2	25.4
Mkt cap (USD m)			532
3m avg. daily turnover (USD m)			2.8
Free float (%)			0
Major shareholder	Masc	hamadol fa	mily (68%)
12m high/low (THB)		8	3.18/41.50
Issued shares (m)			264.00

Sources: Bloomberg consensus; FSSIA estimates



Sureeporn Teewasuwet

Fundamental Investment Analyst on Securities; License no. 040694 sureeporn.t@fssia.com, +66 2646 9972

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Investment thesis

We expect Thailand's cosmetic surgery market to grow by 9.7% CAGR in 2023-30, close to global cosmetic surgery markets. Additionally, the medical tourism trend should support surgery hospitals in Thailand to have a higher revenue mix from international customers, which would in turn support future growth.

MASTER has several strengths. It has earned a good reputation and has become well-known over the past ten years. Given the experience of Dr. Raweewat Maschamadol and other renowned doctors, MASTER has gained customer trust, leading to referrals and positive reviews on social media. It has also expanded and invested in other businesses to further its long-term growth.


Company profile

MASTER is in the cosmetic surgery hospital business under Masterpiece Hospital. Established in 2012, it has 17 operating beds and offers one-stop cosmetic surgery services. MASTER earns revenue from four services, including surgery, skin, hair treatment, and aftercare, with surgery contributing the highest revenue of 81% of total revenue.

www.masterpiecehospital.com

Principal activities (revenue, 2023)

- Surgery 81.0 %
- Skin 7.1 %
- Hair treatment 6.0 %
- Aftercare 3.6 %
- Others 2.3 %




Source: Master Style

Major shareholders

■ Maschamadol family - 68.0 %

■ Others - 32.0 %



Source: Master Style

Catalysts

2024 potential growth drivers include 1) more surgery customers; 2) a higher utilization rate for operating beds, which would drive operating leverage; and 3) the realization of profit and synergies from M&As.

Risks to our call

Downside risks to our P/E-based TP include 1) increased competition; 2) a pandemic that results in a lockdown; 3) lower-than-expected utilization rate of new operating beds; 4) higher-than-expected doctor costs and expenses; and 5) a loss contribution from the acquired units.

Event calendar

Date	Event
May 2024	1Q24 results announcement

Key assumptions

	2024E	2025E	2026E
Total OR rooms (no.)	17	17	17
Capacity hours (hours)	80,665	80,665	80,665
Operating hours (hours)	58,079	60,499	64,532
Utilization rate (%)	72.0	75.0	80.0

Source: FSSIA estimates

Earnings sensitivity

- For every 5% increase in revenue, we estimate 2024 net profit to rise by 3.9%, and vice versa, all else being equal.
- For every 0.5% increase in GPM, we estimate 2024 net profit to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in SG&A, we estimate 2024 net profit to fall by 3.5%, and vice versa, all else being equal.

Source: FSSIA estimates

Exhibit 1: MASTER – 4Q23 earnings results

	4Q22	1Q23	2Q23	3Q23	4Q23	Cha	nge	2022	2023	Change
	(THB m)	(q-q%)	(y-y%)	(THB m)	(THB m)	(y-y%)				
Sales	471	436	459	479	543	13.2	15.1	1,483	1,917	29.3
Cost of sales	210	182	204	200	198	(1.4)	(5.7)	641	785	22.4
Gross profit	262	253	255	279	345	23.7	31.8	841	1,132	34.5
SG&A	161	162	158	160	154	(4.1)	(4.7)	463	634	37.0
Operating profit	103	94	106	128	197	53.3	91.6	386	525	35.9
Profit sharing	0	0	0	0	5	nm	nm	0	5	nm
Interest expense	3	3	4	4	3	(5.4)	(4.7)	9	14	51.5
Tax expense	21	19	21	25	40	60.0	95.3	76	105	37.3
Reported net profit	79	72	81	100	164	63.8	107.8	301	416	38.4
Core profit	79	72	81	100	164	63.8	107.8	301	416	38.4
Key Ratios (%)						(ppt)	(ppt)			
Gross margin	55.5	58.2	55.5	58.2	63.6	5.4	8.0	56.7	59.1	2.3
SG&A to sales	34.2	37.2	34.3	33.5	28.3	(5.1)	(5.9)	31.2	33.1	1.9
Operating margin	21.8	21.5	23.1	26.8	36.3	9.5	14.5	26.1	27.4	1.3
Net margin	16.7	16.4	17.7	20.8	30.1	9.3	13.4	20.3	21.7	1.4
Core margin	16.7	16.4	17.7	20.8	30.1	9.3	13.4	20.3	21.7	1.4
Operating Statistics										
Revenue breakdown (THB m)										
Surgery	389	340	364	387	462	19.3	18.9	1,194	1,553	30.1
Skin	38	42	34	33	27	(17.4)	(28.2)	106	136	28.4
Hair treatment	21	28	32	31	24	(23.3)	12.3	90	115	27.8
Aftercare	18	18	18	17	17	3.1	(2.3)	62	70	11.9
Other	6	8	11	11	13	9.9	96.0	31	44	40.3


Source: MASTER

Exhibit 2: Changes in key assumptions for MASTER

		Forecast			Previous		Change		
	2024E	2025E	2026E	2024E	2025E	2026E	2024E	2025E	2026E
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(%)	(%)	(%)
Total revenue	2,326	2,556	2,861	2,216	2,517	2,842	5.0	1.5	0.7
Costs	949	1,038	1,159	920	1,040	1,165	3.2	(0.2)	(0.6)
Gross profit	1,377	1,518	1,702	1,296	1,478	1,677	6.2	2.8	1.5
SG&A expense	768	844	944	731	831	938	5.0	1.5	0.7
Interest expense	15	15	15	14	13	12	6.3	11.9	18.1
Profit sharing	125	137	144	105	112	124	19.0	22.3	16.1
Reported net profit	621	685	763	536	607	703	16.0	12.9	8.5
Core profit	621	685	763	536	607	703	16.0	12.9	8.5
Key ratios (%)									
Total revenue growth	21.4	9.9	11.9	15.6	13.6	12.9			
Net profit growth	49.2	10.3	11.3	28.7	13.3	15.9			
Core profit growth	49.2	10.3	11.3	28.7	13.3	15.9			
Gross margin	59.2	59.4	59.5	58.5	58.7	59.0	0.7	0.7	0.5
SG&A to sales	33.0	33.0	33.0	33.0	33.0	33.0	0.0	0.0	0.0
Net margin	26.7	26.8	26.7	24.2	24.1	24.7	2.5	2.7	1.9
Core margin	26.7	26.8	26.7	24.2	24.1	24.7	2.5	2.7	1.9
Profit sharing to net profit	20.1	20.0	18.9	19.6	18.5	17.6	0.5	1.5	1.2
Operating statistics									
Total OR rooms (no.)	17	17	17	17	17	17	0.0	0.0	0.0
Capacity hours (hours)	80,665	80,665	80,665	88,330	88,330	88,330	(8.7)	(8.7)	(8.7)
Operating hours (hours)	58,079	60,499	64,532	54,272	58,866	63,460	7.0	2.8	1.7
Utilization rate (%)	72.0	75.0	80.0	61.4	66.6	71.8	17.2	12.5	11.4


Source: FSSIA estimates

Exhibit 3: Operating hours and utilization rate




Sources: MASTER; FSSIA estimates

Exhibit 5: Total revenue and growth




Sources: MASTER; FSSIA estimates

Exhibit 7: Profit sharing and % to net profit




Sources: MASTER; FSSIA estimates

Exhibit 4: Revenue breakdown by service type




Sources: MASTER; FSSIA estimates

Exhibit 6: Gross margin and SG&A to sales



Sources: MASTER; FSSIA estimates

Exhibit 8: Net profit and growth



Sources: MASTER; FSSIA estimates

Financial Statements

Master Style

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	1,483	1,917	2,326	2,556	2,861
Cost of goods sold	(641)	(785)	(949)	(1,038)	(1,159)
Gross profit	841	1,132	1,377	1,518	1,702
Other operating income	8	27	33	33	37
Operating costs	(463)	(634)	(768)	(844)	(944)
Operating EBITDA	422	586	719	800	902
Depreciation	(35)	(62)	(77)	(92)	(107)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	386	525	642	708	795
Net financing costs	(4)	(9)	(9)	(9)	(9)
Associates	0	5	125	137	144
Recurring non-operating income	0	5	125	137	144
Non-recurring items	0	0	0	0	0
Profit before tax	383	521	758	836	930
Tax	(76)	(105)	(136)	(150)	(167)
Profit after tax	306	416	621	685	763
Minority interests	-	-	-	_	-
Preferred dividends	-	-	_	-	_
Other items	-	-	_	_	_
Reported net profit	306	416	621	685	763
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	306	416	621	685	763
Per share (THB)					
Recurring EPS *	1.61	1.58	2.35	2.60	2.89
Reported EPS	1.61	1.58	2.35	2.60	2.89
DPS	0.30	0.27	0.71	0.00	0.00
Diluted shares (used to calculate per share data)	190	264	264	264	264
Growth					
Revenue (%)	124.8	29.3	21.4	9.9	11.9
Operating EBITDA (%)	73.9	39.1	22.5	11.3	12.8
Operating EBIT (%)	82.7	35.9	22.3	10.3	12.3
Recurring EPS (%)	0.0	(2.2)	49.2	10.3	11.3
Reported EPS (%)	0.0	(2.2)	49.2	10.3	11.3
Operating performance					
Gross margin inc. depreciation (%)	56.7	59.1	59.2	59.4	59.5
Gross margin exc. depreciation (%)	59.1	62.3	62.5	63.0	63.2
Operating EBITDA margin (%)	28.4	30.6	30.9	31.3	31.5
Operating EBIT margin (%)	26.1	27.4	27.6	27.7	27.8
Net margin (%)	20.7	21.7	26.7	26.8	26.7
Effective tax rate (%)	19.9	20.1	18.0	18.0	18.0
Dividend payout on recurring profit (%)	18.6	17.0	30.0	10.0	10.0
Interest cover (X)	102.2	62.2	81.8	90.8	101.7
Inventory days	26.8	41.1	42.8	42.0	41.8
Debtor days	0.9	1.1	1.1	1.0	0.9
Creditor days	34.7	64.9	62.6	47.2	47.0
Operating ROIC (%)	115.1	37.7	33.0	43.0	46.8
ROIC (%)	82.1	25.8	20.2	43.0 19.2	20.4
ROE (%)	82.1 107.4	25.8 24.5	20.2 19.4	18.9	18.8
	40.0	24.5 18.5	16.4	16.3	16.3
ROA (%) * Pre-exceptional, pre-goodwill and fully diluted	40.0	10.0	10.4	10.3	10.3
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Surgery	1,194	1,553	1,908	2,087	2,337
Skin	106	136	161	185	210
Hair treatment	90	115	136	154	175
Aftercare	90 62	70	75	82	88
Aftercare	02	70	/5	82	88

Sources: Master Style; FSSIA estimates

Financial Statements

Master Style

iviastei Style					
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	306	416	621	685	763
Depreciation	35	62	77	92	107
Associates & minorities Other non-cash items	0	0 (5)	0 (125)	0 (137)	0 (144)
Change in working capital	(100)	74	(38)	18	9
Cash flow from operations	242	547	534	658	735
Capex - maintenance	-	-	-	-	-
Capex - new investment	(413)	(2,179)	(673)	(171)	(107)
Net acquisitions & disposals	-	-	-	-	-
Other investments (net)	-	-	-	-	-
Cash flow from investing	(413)	(2,179)	(673)	(171)	(107)
Dividends paid Equity finance	(263) 198	(99) 2,270	(189) 0	(274) 0	(305)
Debt finance	159	(11)	(2)	(2)	(2)
Other financing cash flows	(1)	2	0	0	1
Cash flow from financing	93	2,161	(190)	(275)	(306)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	(5)	0	0	0	0
Movement in cash	(83)	529	(329)	212 501.30	321 641.77
Free cash flow to firm (FCFF) Free cash flow to equity (FCFE)	(162.06) (18.91)	(1,618.40) (1,641.98)	(124.30) (140.59)	485.66	626.34
	(10.51)	(1,041.50)	(140.00)	+00.00	020.04
Per share (THB)	(0.64)	(6.12)	(0.47)	1.90	2.43
FCFF per share FCFE per share	(0.61) (0.07)	(6.13) (6.22)	(0.47) (0.53)	1.90 1.84	2.43
Recurring cash flow per share	1.80	1.79	2.17	2.42	2.75
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross) Less: Accumulated depreciation	498 (73)	1,242 (339)	1,578 (366)	1,665 (395)	1,740 (427)
Tangible fixed assets (net)	424	903	1, 211	1,270	1,313
Intangible fixed assets (net)	7	7	7	7	7
Long-term financial assets	8	15	15	15	15
Invest. in associates & subsidiaries	0	362	1,861	2,019	2,060
Cash & equivalents	98	627	298	509	830
A/C receivable	5	7	6	7	8
Inventories	63	101	104	114	127
Other current assets	166 331	1,136	302 710	281 911	315 1,280
Current assets Other assets	177	1,871 480	233	256	286
Total assets	947	3,637	4,037	4,477	4,961
Common equity	404	2,991	3,424	3,835	4,292
Minorities etc.	0	0	0	0	0
Total shareholders' equity	404	2,991	3,424	3,835	4,292
Long term debt	291	294	292	291	289
Other long-term liabilities	3	5	5	5	6
Long-term liabilities	294	298	297	296	295
A/C payable	148 15	260 2	210 2	230 2	257 2
Short term debt Other current liabilities	86	2 86	105	2 115	114
Current liabilities	249	348	316	347	373
Total liabilities and shareholders' equity	947	3,637	4,037	4,477	4,961
Net working capital	0	898	98	57	78
Invested capital	616	2,664	3,424	3,623	3,758
* Includes convertibles and preferred stock which is being t	treated as debt				
Per share (THB)					
Book value per share	2.12	11.33	12.97	14.53	16.26
Tangible book value per share	2.09	11.30	12.94	14.50	16.23
Financial strength					
Net debt/equity (%)	51.7	(11.1)	(0.1)	(5.7)	(12.6)
Net debt/total assets (%)	22.1	(9.1)	(0.1)	(4.8)	(10.9)
Current ratio (x) CF interest cover (x)	1.3 105.2	5.4 64.0	2.2 57.8	2.6 71.6	3.4 80.5
Valuation	2022	2023	2024E	2025E	2026E
Recurring P/E (x) *	45.1	46.1	30.9	28.0	25.2
Recurring P/E @ target price (x) *	50.9	52.0	34.8	31.6	28.4
Reported P/E (x) Dividend yield (%)	45.1 0.4	46.1 0.4	30.9 1.0	28.0	25.2
Price/book (x)	34.2	6.4	1.0 5.6	5.0	4.5
Price/tangible book (x)	34.8	6.4	5.6	5.0	4.5
	2				
EV/EBITDA (x) **	33.3	32.2	26.7	23.7	20.7
	33.3 37.5	32.2 36.4	26.7 30.1	23.7	20.7
EV/EBITDA (x) **					

Sources: Master Style; FSSIA estimates

Disclaimer for ESG scoring

ESG score	Methodolog	Jy			Rating				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process bas from the anr Only the top inclusion.	ne DJSI World applies a transparent, rules-based component selection cocess based on the companies' Total Sustainability Scores resulting om the annual S&P Global Corporate Sustainability Assessment (CSA). Inly the top-ranked companies within each industry are selected for clusion. Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the higher scoring company are disqualified. The constituents of the DJSI indices selected from the Eligible Universe.						an S&P Global of the highest JSI indices are	
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing by Candidates 1) no irregul- float of >150 up capital. S 70%; 2) inde- wrongdoing	quantifies responsibility in Environmental and Social issues by ging business with transparency in Governance, updated annually. dates must pass the preemptive criteria, with two crucial conditions: rregular trading of the board members and executives; and 2) free f > 150 shareholders, and combined holding must be > 15% of paid-bital. Some key disqualifying criteria include: 1) CG score of below 2) independent directors and free float violation; 3) executives' doing related to CG, social & environmental impacts; 4) equity in ve territory; and 5) earnings in red for > 3 years in the last 5 years.							a part of DJSI ted against the se 1) market d 3) liquidity e SETTHSI
by Thai Institute of Directors Association (Thai IOD)	annually by Thailand (SE	the Thai IOD, v	in sustainable developme with support from the Stock is are from the perspective is.	Exchange of	Good (80-89), 3 and not rated for equitable treatm	for Good (70 r scores belo nent of shareh 5%); 4) disclo	ories: 5 for Excell 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 25 sure & transpare	0-69), 1 for P include: 1) th 5% combined	ass (60-69), e rights; 2) and s; 3) the role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	quantifies the extent to which shareholders' rights and equitable eatment are incorporated into business operations and information is an sparent and sufficiently disclosed. All form important elements of two at of five the CG components to be evaluated annually. The assessment iteria cover AGM procedures before the meeting (45%), at the meeting ate (45%), and after the meeting (10%). (The first assesses 1) advance culation of sufficient information for voting; and 2) facilitating how voting rights can be recised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&A. The third involves the meeting minutes that yould contain discussion issues, resolutions and voting results.)							
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key control c Certification is eciding to become Intent to kick off including risk assets	checklist include corruption ols, and the monitoring and s good for three years. e a CAC certified member stan an 18-month deadline to submissment, in place of policy and blishment of whistleblowing chatkeholders.)	d developing of t by submitting a it the CAC Checklist for control, training of	passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.				
Morningstar Sustainalytics	based on an risk is unma regulatory filing information, co	assessment on aged. Sources gs, news and oth	k rating provides an overa f how much of a company' to be reviewed include corpora er media, NGO reports/website , ESG controversies, issuer fee		Low	score is the sum higher ESG risk i Medium 20-30		Severe	
ESG Book	The ESG sc positioned to the principle helps explain over-weighti	ore identifies so outperform over of financial man future risk-ad	ustainable companies that ver the long term. The mett teriality including informati justed performance. Mater h higher materiality and re	hodology considers ion that significantly riality is applied by	The total ESG score is calculated as a weighted sum of the feature scores using materiality-based weights. The score is scaled between and 100 with higher scores indicating better performance.				
MSCI			neasure a company's man						nethodology to
	•		d laggards according to the	eir exposure to ESG ri	isks and how well	they manage	those risks relati	ve to peers.	
	AAA AA	8.571-10.000 7.143-8.570	Leader:	leading its industry in m	nanaging the most sign	gnificant ESG ri	sks and opportunitie	s	
	AA	5.714-7.142							
	BBB	4.286-5.713	Average:	a mixed or unexception	nal track record of ma	naging the mos	st significant ESG ris	ks and opportur	nities relative to
	ВВ	2.857-4.285		industry peers					
	В	1.429-2.856							
	ccc	0.000-1.428	Laggard:	lagging its industry bas	ea on its high exposi	are and failure to	o manage significan	ESG risks	
Moody's ESG solutions	believes that	t a company in	ree to which companies tal tegrating ESG factors into r shareholders over the me	its business model an					
Refinitiv ESG rating	based on pu	blicly available	and objectively measure a and auditable data. The s a publicly. (Score ratings are	core ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of ti	
S&P Global			e is a relative score measun the same industry classif				of ESG risks, opp	oortunities, an	d impacts
Bloomberg	ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.								
Bloomberg	ESG Disclos	sure Score		closure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of ery data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.					

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Sureeporn Teewasuwet FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Sureeporn Teewasuwet started covering this stock from 12-Dec-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Master Style	MASTER TB	THB 72.75	BUY	Downside risks to our P/E-based TP include 1) increased competition, 2) a pandemic that results in a lockdown, 3) lower-than-expected utilization rate of new operating beds, 4) higher-than-expected doctor costs and expenses, and 5) a loss contribution from the acquired units.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 23-Feb-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.